DTE Energy sets 2019 annual meeting date
Get Alerts DTE Hot Sheet
Join SI Premium – FREE
DETROIT, Dec. 6, 2018 /PRNewswire/ -- The DTE Energy (NYSE: DTE) Board of Directors yesterday announced that its 2019 Annual Meeting of Common Stock Shareholders will be Thursday, May 9.

Shareholders of record at the close of business March 12, 2019 are eligible to vote at the meeting. Shareholders interested in proposing business from the floor or nominating a person for the position of director from the floor must give notice and certain information to the DTE Energy corporate secretary by the close of business on Jan. 3, 2019.
About DTE EnergyDTE Energy (NYSE: DTE) is a Detroit-based diversified energy company involved in the development and management of energy-related businesses and services nationwide. Its operating units include an electric utility serving 2.2 million customers in Southeastern Michigan and a natural gas utility serving 1.3 million customers in Michigan. The DTE Energy portfolio includes non-utility energy businesses focused on power and industrial projects, natural gas pipelines, gathering and storage, and energy marketing and trading. As one of Michigan's leading corporate citizens, DTE Energy is a force for growth and prosperity in the 450 Michigan communities it serves in a variety of ways, including philanthropy, volunteerism and economic progress. Information about DTE Energy is available at dteenergy.com, twitter.com/dte_energy and facebook.com/dteenergy.
View original content to download multimedia:http://www.prnewswire.com/news-releases/dte-energy-sets-2019-annual-meeting-date-300761189.html
SOURCE DTE Energy
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lithosphere Advances Web4 Access with Thanos, a Multi-Chain Agentic Wallet for Users and Autonomous Agents
- SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
- Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share